Phase 2 DAVIO 2 Clinical Trial Topline Results (Wet AMD)

Other Clinical Trials - EYP-1901

Phase 2 DAVIO 2 Sub-Group Analysis (Wet AMD)

Patients Anti-VEGF Supplement-Free Up to 6 Months

Phase 2 PAVIA Clinical Trial in Non-Proliferative Diabetic Retinopathy (NPDR)

Randomized Double-Masked, EYP-1901 Single Injection with Sham Control as a 9-Month Treatment in NPDR

Phase 2 VERONA Clinical Trial in Diabetic Macular Edema (DME)

Randomized, Open-Label, Aflibercept Controlled Trial with a Single EYP-1901 Injection